Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection

American Journal of Epidemiology

Volumn 161, Issue 11, 2005, Pages 999-1012

  Vlahov, David ^a,b   Galai, Noya ^b   Safaeian, Mahboobeh ^b   Galea, Sandro ^a   Kirk, Gregory D ^b   Lucas, Greg M ^c   Sterling, Timothy R ^c,d  

^a NEW YORK ACADEMY OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy, highly active; HIV; Substance abuse, intravenous; Substance related disorders; Survival; Treatment outcome

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; METHADONE;

DRUG USER; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 19544379027     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi133     Document Type: Article

References (40)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-503.
3. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355:1158-9.
4. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
5. Anastos K, Barron Y, Miotti P, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002;162:1973-80.
6. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
7. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
8. Poundstone K, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15: 1115-23.
9. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus related mortality in Chicago in women, African Americans, and injection drug users 1995-1997. Arch Intern Med 2000;160:365-9.
10. Centers for Disease Control and Prevention. Estimated incidence of AIDS and deaths of persons with AIDS adjusted for delays in reporting, by quarter-year of diagnosis/death, United States, 1985-1987. HIV/AIDS Surveill Rep 1997;9:1-44.
11. Chaisson MA, Berenson L, Li W, et al. Declining AIDS mortality in New York City. J Acquir Immune Defic Syndr 1999;21:59-64.
12. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280: 544-6.
13. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-9.
14. Celentano DD, Galai N, Sehti AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-15.
15. Vlahov D, Wang CL, Galai N, et al. Mortality risk among new onset injection drug users. Addiction 2004;99:946-54.
16. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Department of Health and Human Services, July 14, 2003. (http://www. aidsinfo.nih.gov/guidelines).
17. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004;292:251-65.
18. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE Study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991;109:75-100.
19. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002;113:91-8.
20. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
21. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996;124:999-1005.
22. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
23. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001;15:2251-7.
24. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002;155:760-70.
25. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-6.
26. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277: 959-65.
27. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR2 promoter mutation. Nat Med 1998;4: 350-3.
28. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273: 1856-62.
29. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277:959-65.
30. Martin MP, Dean M, Smith MW, et al. Genetic acceleration by a promoter variant of CCR5. Science 1998;282:1907-11.
31. Winkler CA, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998;279:389-93.
32. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 2000;97:14467-72.
33. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002;99:10002-7.
34. Duggal P, An P, Beaty TH, et al. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun 2003;4:245-50.
35. Graham NM, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-1 seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991;4:267-76.
36. Ellis RJ, Childers ME, Cherner M, et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003;188:182G-6.
37. Lange WR, Snyder FR, Lozovsky D, et al. Geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. Am J Public Health 1988;78:443-6.
38. Vlahov D, Brewer F, Munoz A, et al. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987. J Aquir Immune Defic Syndr 1989;2:283-90.
39. Wang CL, Vlahov D, Galai N, et al. Mortality among HIV-seropositive vs. seronegative persons in the HAART era: implications for when to initiate therapy. J Infect Dis 2004;190:1046-54.
40. Samuels JF, Vlahov D, Anthony JC, et al. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict 1992;87:417-28.